Nature Search

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

The authors present the results of a 24-month phase 2 study of AADvac1, a tau vaccine against Alzheimer’s disease. AADvac1 was safe and induced high levels of antibodies. In the whole study sample, there were no significant changes on clinical outcomes.

Petr Novak
Branislav Kovacech
Norbert Zilka
Research14 Jun 2021
Nature Aging

Volume: 1, P: 521-534
Transferability of European-derived Alzheimer’s disease polygenic risk scores across multiancestry populations

Polygenic risk scores for Alzheimer’s disease derived from individuals of European ancestry can show improved performance in multiancestry settings after incorporating genome-wide association summary statistics from diverse populations.

Aude Nicolas
Richard Sherva
Jean-Charles Lambert
ResearchOpen Access18 Jun 2025
Nature Genetics

P: 1-13
White matter hyperintensities, cognitive impairment and dementia: an update

White matter hyperintensities (WMHs) are frequently seen on brain MRI in older people, and are thought to result from chronic ischaemia associated with cerebral small vessel disease. Prins and Scheltens provide a timely Review on WMHs, including their relationship with cognitive decline and dementia. The authors also discuss how WMHs might provide a therapeutic target to prevent the onset and progression of dementia.

Niels D. Prins
Philip Scheltens
Reviews17 Feb 2015
Nature Reviews Neurology

Volume: 11, P: 157-165
Plasma and MRI biomarkers capture neuronal damage in former professional boxers

Suzie Kamps
Suzan van Amerongen
Everard G. B. Vijverberg
ResearchOpen Access06 Jun 2025
Scientific Reports

Volume: 15, P: 1-13
New insights into the genetic etiology of Alzheimer’s disease and related dementias

Meta-analysis of genome-wide association studies on Alzheimer’s disease and related dementias identifies new loci and enables generation of a new genetic risk score associated with the risk of future Alzheimer’s disease and dementia.

Céline Bellenguez
Fahri Küçükali
Jean-Charles Lambert
ResearchOpen Access04 Apr 2022
Nature Genetics

Volume: 54, P: 412-436
PLD3 variants in population studies

Sven J. van der Lee
Henne Holstege
Cornelia M. van Duijn
Research01 Apr 2015
Nature

Volume: 520, P: E2-E3
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

The authors show in an animal model and in a study in patients with dementia with Lewy bodies (DLB) that the drug neflamapimod has potential to treat diseases, such as DLB, associated with loss of neurons that produce the neurotransmitter acetylcholine.

Ying Jiang
John J. Alam
Ralph A. Nixon
ResearchOpen Access21 Sept 2022
Nature Communications

Volume: 13, P: 1-15
Microbleeds in dementia—singing a different ARIA

In 2011, researchers used imaging techniques to investigate brain microbleeds in patients with dementia and highlighted how lobar microbleeds could be used as a marker for amyloid pathology and for predicting mortality. New guidelines on the inclusion and exclusion of participants with microbleeds in anti-amyloid clinical trials were also published.

Philip Scheltens
Jeroen D. C. Goos
News & Views10 Jan 2012
Nature Reviews Neurology

Volume: 8, P: 68-70
Can lumbar puncture help to identify patients with incipient Alzheimer's disease?

Femke H Bouwman
Wiesje M van der Flier
Philip Scheltens
Comments & Opinion01 Oct 2006
Nature Clinical Practice Neurology

Volume: 2, P: 530-531
Mild cognitive impairment—amyloid and beyond

Recently developed criteria for diagnosis of mild cognitive impairment due to Alzheimer disease make use of clinical and biomarker information. A new study reports that these criteria apply in both community and research settings; however, results from the community-based cohort conflict with a proposed biomarker-based model of disease progression.

Philip Scheltens
News & Views23 Jul 2013
Nature Reviews Neurology

Volume: 9, P: 493-495
Resting-state oscillations reveal disturbed excitation–inhibition ratio in Alzheimer’s disease patients

Anne M. van Nifterick
Danique Mulder
Alida A. Gouw
ResearchOpen Access07 May 2023
Scientific Reports

Volume: 13, P: 1-13
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

Known genetic loci account for only a fraction of the genetic contribution to Alzheimer’s disease. Here, the authors have performed a large genome-wide meta-analysis comprising 409,435 individuals to discover 6 new loci and demonstrate the efficacy of an Alzheimer’s disease polygenic risk score.

Itziar de Rojas
Sonia Moreno-Grau
Agustín Ruiz
ResearchOpen Access07 Jun 2021
Nature Communications

Volume: 12, P: 1-16
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

An increasing array of biomarkers available in blood, cerebrospinal fluid and through imaging are providing valuable proxies of disease processes in neurodegenerative disorders (NDDs). In their Review, Cummings and co-authors discuss the implementation of biomarkers in clinical trials across various NDDs, focusing on the context of use, to help expedite and de-risk drug development.

Jeffrey L. Cummings
Charlotte E. Teunissen
Philip Scheltens
Reviews04 Apr 2025
Nature Reviews Drug Discovery

P: 1-21
Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression

Aβ34 is generated from degradation of Aβ40 and Aβ42 by β-secretase. Here, the authors show that Aβ34 is a marker for amyloid clearance and is elevated in the CSF of patients that go on to convert from mild cognitive impairment to Alzheimer’s disease, suggesting it may be a useful biomarker.

Filip Liebsch
Luka Kulic
Gerhard Multhaup
ResearchOpen Access20 May 2019
Nature Communications

Volume: 10, P: 1-15
Hippocampal volume loss and Alzheimer disease progression

The progression of Alzheimer disease might be monitored by measuring the rate of hippocampal volume loss by means of MRI. Research suggests that a reduction in hippocampal volume can be detected over a period as short as 6 months, and that such volume loss is associated with cognitive decline and other indicators of Alzheimer disease neuropathology.

Wiesje M. van der Flier
Philip Scheltens
News & Views01 Jul 2009
Nature Reviews Neurology

Volume: 5, P: 361-362
Revised criteria for the diagnosis and staging of Alzheimer’s disease

Alzheimer’s disease can be treated by targeting amyloid-β plaques and diagnosed in vivo by biomarkers, prompting the revision of criteria for the diagnosis and staging of this disease.

Clifford R. Jack Jr
Scott J. Andrews
Maria C. Carrillo
Comments & Opinion28 Jun 2024
Nature Medicine

Volume: 30, P: 2121-2124
X‐chromosome-wide association study for Alzheimer’s disease

Julie Le Borgne
Lissette Gomez
Céline Bellenguez
ResearchOpen Access04 Dec 2024
Molecular Psychiatry

Volume: 30, P: 2335-2346
The clinical use of structural MRI in Alzheimer disease

MRI-based structural imaging has become an integral component of the clinical assessment of patients with suspected Alzheimer disease (AD), and atrophy of medial temporal structures is now considered to be a valid diagnostic marker at the mild cognitive impairment stage. In this article, Frisoni et al. consider the roles of structural MRI markers in the diagnosis of AD and non-AD dementias, and in the tracking of disease progression during clinical trials.

Giovanni B. Frisoni
Nick C. Fox
Paul M. Thompson
Reviews01 Feb 2010
Nature Reviews Neurology

Volume: 6, P: 67-77
Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care

Conor MW Douglas
Philip Scheltens
Reviews17 Sept 2014
European Journal of Human Genetics

Volume: 23, P: 736-738
Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease

Multistage gene burden analysis in exome sequencing data from 32,558 individuals identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease.

Henne Holstege
Marc Hulsman
Jean-Charles Lambert
ResearchOpen Access21 Nov 2022
Nature Genetics

Volume: 54, P: 1786-1794
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia

Evolutionarily conserved gene modules mediate neurodegenerative dementia in a variety of mouse models and in postmortem brain tissue from patients.

Vivek Swarup
Flora I. Hinz
Daniel H. Geschwind
Research03 Dec 2018
Nature Medicine

Volume: 25, P: 152-164
Publisher Correction: LifeTime and improving European healthcare through cell-based interceptive medicine

Nikolaus Rajewsky
Geneviève Almouzni
Frauke Zipp
Amendments and CorrectionsOpen Access17 Mar 2021
Nature

Volume: 592, P: E8
Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

Itziar de Rojas
Sonia Moreno-Grau
Agustín Ruiz
Amendments and CorrectionsOpen Access09 Feb 2023
Nature Communications

Volume: 14, P: 1-2
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

Alexander Neumann
Fahri Küçükali
Kristel Sleegers
ResearchOpen Access16 Feb 2022
Molecular Psychiatry

Volume: 27, P: 1990-1999
LifeTime and improving European healthcare through cell-based interceptive medicine

The LifeTime initiative is an ambitious, multidisciplinary programme that aims to improve healthcare by tracking individual human cells during disease processes and responses to treatment in order to develop and implement cell-based interceptive medicine in Europe.

Nikolaus Rajewsky
Geneviève Almouzni
Frauke Zipp
Reviews07 Sept 2020
Nature

Volume: 587, P: 377-386
Biomarker-based staging of Alzheimer disease: rationale and clinical applications

Recent clinical trials have highlighted the need for Alzheimer disease (AD) staging rather than simply noting the presence or absence of AD pathology. This article reviews current biomarker-based AD staging systems and outlines hypothetical frameworks to stage AD severity using fluid biomarkers.

Joseph Therriault
Suzanne E. Schindler
Pedro Rosa-Neto
Reviews01 Mar 2024
Nature Reviews Neurology

Volume: 20, P: 232-244
Vascular cognitive impairment

Vascular cognitive impairment (VCI) refers to any degree of cognitive impairment (from mild cognitive impairment to dementia) that is associated with vascular pathology. This Primer by van der Flier et al. describes the epidemiology, mechanisms, diagnosis and management of VCI.

Wiesje M. van der Flier
Ingmar Skoog
Philip Scheltens
Reviews15 Feb 2018
Nature Reviews Disease Primers

Volume: 4, P: 1-16
Advances in the early detection of Alzheimer's disease

Peter J Nestor
Philip Scheltens
John R Hodges
Reviews01 Jul 2004
Nature Medicine

Volume: 10, P: S34-S41
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

The amyloid hypothesis has been the dominant model for the pathogenesis of Alzheimer disease for several decades. In this Perspective, Giovanni Frisoni and colleagues examine evidence for and against this hypothesis before outlining an alternative model, the probabilistic model of Alzheimer disease.

Giovanni B. Frisoni
Daniele Altomare
Bruno Dubois
Reviews23 Nov 2021
Nature Reviews Neuroscience

Volume: 23, P: 53-66
α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies

Frederique J. Hart de Ruyter
Tjado H. J. Morrema
Jeroen J. M. Hoozemans
ResearchOpen Access28 Aug 2023
npj Parkinson's Disease

Volume: 9, P: 1-9
Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

Elisabeth H. Thijssen
Inge M. W. Verberk
Charlotte E. Teunissen
ResearchOpen Access06 May 2021
Scientific Reports

Volume: 11, P: 1-10
Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

Shengjun Hong
Dmitry Prokopenko
Lars Bertram
ResearchOpen Access22 Nov 2020
Translational Psychiatry

Volume: 10, P: 1-12
Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions

Lianne M. Reus
Iris E. Jansen
Sven J. van der Lee
ResearchOpen Access02 Sept 2021
Translational Psychiatry

Volume: 11, P: 1-8
Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease

Niccolò Tesi
Sven J. van der Lee
Henne Holstege
ResearchOpen Access29 Sept 2020
Translational Psychiatry

Volume: 10, P: 1-12
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers

Shahzad Ahmad
Marta del Campo Milan
Cornelia M. van Duijn
ResearchOpen Access19 May 2020
Scientific Reports

Volume: 10, P: 1-13
Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer’s disease

Niccolò Tesi
Sven J. van der Lee
Henne Holstege
ResearchOpen Access26 Sept 2018
European Journal of Human Genetics

Volume: 27, P: 244-253
A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease

Tobias Skillbäck
Niklas Mattsson
Johan Gobom
ResearchOpen Access17 Oct 2017
Scientific Reports

Volume: 7, P: 1-12
Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer’s disease

Sara Hijazi
Tim S. Heistek
Ronald E. van Kesteren
ResearchOpen Access20 Aug 2019
Molecular Psychiatry

Volume: 25, P: 3380-3398
Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy

Henne Holstege
Sven J van der Lee
Philip Scheltens
ResearchOpen Access24 May 2017
European Journal of Human Genetics

Volume: 25, P: 973-981
Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis

Yixin Gao
Ting Wang
Ping Zeng
ResearchOpen Access22 Jul 2020
Scientific Reports

Volume: 10, P: 1-12
Raloxifene Treatment Enhances Brain Activation during Recognition of Familiar Items: a Pharmacological fMRI Study in Healthy Elderly Males

Rutger Goekoop
Frederik Barkhof
Serge ARB Rombouts
Research16 Nov 2005
Neuropsychopharmacology

Volume: 31, P: 1508-1518

Search

Filter By:

Search

Quick links